FAQ: Onassis Holdings Regulation A+ Financing with Dalmore Group

What is the main announcement from Onassis Holdings?

Onassis Holdings has launched a Regulation A+ financing round through an agreement with Dalmore Group, enabling the company to raise up to $75 million annually from the public.

Why is this financing round significant for Onassis Holdings?

This financing allows Onassis Holdings to access public capital markets for funding its biotech initiatives, specifically in longevity and rejuvenation technologies through epigenetic reprogramming.

How does the Regulation A+ financing work?

Regulation A+ allows companies to raise capital from the public, and Dalmore Group provides marketing, PR support, marketplace syndication, and secondary trading solutions to facilitate this process.

Who is Dalmore Group and what is their role?

Dalmore Group is a financial services firm with over 16 years of experience that has onboarded more than 270 Reg A+ issuers since 2021, providing marketing, PR support, and trading solutions for Onassis Holdings.

What is Onassis Holdings’ business focus?

Onassis Holdings is a biotech holding company specializing in longevity and rejuvenation technologies through epigenetic reprogramming, with a subsidiary called Ananda Labs focused on groundbreaking therapies using patented proteins.

Where can I find more information about Onassis Holdings?

You can learn more about the company by visiting their website at https://www.onassis-holdings.com/ or viewing the full press release at https://ibn.fm/s9HOQ.

What is the maximum amount Onassis can raise through this financing?

The company can raise up to $75 million annually through this Regulation A+ financing initiative with Dalmore Group.

What specific technology is Onassis developing through its subsidiary?

Through its subsidiary Ananda Labs, Onassis is developing therapies based on patented proteins that rejuvenate elderly cells while maintaining their distinct properties.